Jun 01, 2020
CytRx Corporation Highlights Orphazyme's Rolling Submission of its New Drug Application with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C
Apr 29, 2020
CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Orphazyme A/S in Niemann-Pick Disease
Feb 11, 2020
CytRx Corporation Highlights Recently Published Data of its Licensee Orphazyme A/S Phase 2 Trial of Arimoclomol in the Treatment of Sporadic Inclusion Body Myositis (sIBM)
Feb 04, 2020
CytRx Corporation Highlights Updated Arimoclomol Milestone Guidance Provided by Licensee Orphazyme A/S
Jan 30, 2020
Positive topline results demonstrated by olipudase alfa, first and only investigational therapy in late-stage development for acid sphingomyelinase deficiency
Dec 19, 2019
CytRx Corporation Highlights Significant Positive Events From its Two Licensed Drugs Arimoclomol and Aldoxorubicin
Aug 28, 2019
Niemann-Pick Disease Type C (NPC) Insights, Epidemiology, and Market Forecasts, 2028
Jul 30, 2019
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Prepares for Regulatory Filing of Arimoclomol in U.S. for Niemann-Pick Disease Type C
May 02, 2019
CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S
Sep 13, 2018
CytRx Corporation Announces Receipt of Milestone Payment from Orphazyme A/S
Oct 30, 2017
Tampa Bay Cyclist Will Ride Coast to Coast to Find a Cure for Niemann-Pick Type C
Oct 18, 2017
When Life Gives You Lemons...Help Save Lives and Take the #NoPuckerChallenge To Raise Awareness for Niemann-Pick Type C